株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ウイルス性結膜炎 : パイプライン製品の分析

Viral Conjunctivitis - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 201009
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.05円で換算しております。
Back to Top
ウイルス性結膜炎 : パイプライン製品の分析 Viral Conjunctivitis - Pipeline Review, H1 2017
出版日: 2017年03月31日 ページ情報: 英文 43 Pages
概要

ウイルス性結膜炎は、よく見られる自己限定性の疾患で、通常、アデノウイルスが原因となって引き起こされます。ウィルス性結膜炎は発病してから目の赤い間は非常に伝染しやすく、それは通常10〜12日間です。徴候は、目のかゆみ、涙目、赤目、膿、光に対する過敏症(角膜が関連)などがあります。 治療は、潤滑剤、血管収縮薬、抗ヒスタミン剤を用います。

当レポートでは、ウイルス性結膜炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

ウイルス性結膜炎の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Adenovir Pharma AB
  • NanoViricides, Inc.
  • Panoptes Pharma Ges.m.b.H.
  • Shire Plc
  • Starpharma Holdings Limited

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9104IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Viral Conjunctivitis - Pipeline Review, H1 2017, provides an overview of the Viral Conjunctivitis (Ophthalmology) pipeline landscape.

Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors and antihistamines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Viral Conjunctivitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Viral Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Viral Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 5 respectively.

Viral Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Viral Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Viral Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Viral Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Viral Conjunctivitis (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Viral Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Viral Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Viral Conjunctivitis - Overview
    • Viral Conjunctivitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Viral Conjunctivitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Viral Conjunctivitis - Companies Involved in Therapeutics Development
    • Adenovir Pharma AB
    • Marinomed Biotechnologie GmbH
    • NanoViricides Inc
    • Panoptes Pharma GesmbH
    • Shire Plc
    • Starpharma Holdings Ltd
  • Viral Conjunctivitis - Drug Profiles
    • APD-209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APD-514 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • astodrimer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EKCCide-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • iota-carrageenan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OKG-0301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHP-640 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Viral Conjunctivitis - Dormant Projects
  • Viral Conjunctivitis - Discontinued Products
  • Viral Conjunctivitis - Product Development Milestones
    • Featured News & Press Releases
      • May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment
      • Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis
      • Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis
      • May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Viral Conjunctivitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Viral Conjunctivitis - Pipeline by Adenovir Pharma AB, H1 2017
  • Viral Conjunctivitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2017
  • Viral Conjunctivitis - Pipeline by NanoViricides Inc, H1 2017
  • Viral Conjunctivitis - Pipeline by Panoptes Pharma GesmbH, H1 2017
  • Viral Conjunctivitis - Pipeline by Shire Plc, H1 2017
  • Viral Conjunctivitis - Pipeline by Starpharma Holdings Ltd, H1 2017
  • Viral Conjunctivitis - Dormant Projects, H1 2017
  • Viral Conjunctivitis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Viral Conjunctivitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top